

00 FEB 11 PM 2:52

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers are Required to Complete This Page H

1. Registrant Name Capitol Associates, Inc.			
2. Address <input type="checkbox"/> Check if different than previously reported 426 C Street, NE, Washington, DC 20002			
3. Principal Place of Business (if different from line 2) City: _____ State/Zip (or Country) _____			
4. Contact Name Debra M. Hardy Havens	Telephone (202) 544-1880	E-mail (optional) dh@capitolassociates.com	5. Senate ID # 8101-277
7. Client Name Glaxo Wellcome, Inc.	<input type="checkbox"/> Self		6. House ID # 30813023

TYPE OF REPORT 8. Year 1999 Midyear (January 1-June 30) ☐ OR Year End (July 1-December 31) ☒

9. Check if this filing amends a previously filed version of this report ☐

10. Check if this is a Termination Report ☐ ⇒ Termination Date _____

11. No Lobbying Activity ☐

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000 <input type="checkbox"/>	Less than \$10,000 <input type="checkbox"/>
\$10,000 or more <input checked="" type="checkbox"/> ⇒ <u>\$100,000</u> Income (nearest \$20,000)	\$10,000 or more <input type="checkbox"/> ⇒ \$ _____ Expenses (nearest \$20,000)
14. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.	
<input type="checkbox"/> Method A. Reporting amounts using LDA definitions only	
<input type="checkbox"/> Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code	
<input type="checkbox"/> Method C. Reporting amounts under section 162(e) of the Internal Revenue Code	

Signature Debra M. Hardy Havens
Printed Name and Title Debra M. Hardy Havens, CEO

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code BUD (one per page)

16. Specific lobbying issues

Conference Report on H.R. 3194 - Consolidated Appropriations Act for Fiscal Year 2000. Secure support for the National Institutes of Health and within the conference agreement on the Departments of Labor, Health and Human Services, and Education and Related Appropriations bill incorporated in the Consolidated Appropriations Act for Fiscal Year 2000. Overall NIH funding as well as salary cap for investigators and extramural research facilities construction were priorities.

Conference Report on H.R. 3064 - Making Appropriations for the Government of the District of Columbia and other programs for Fiscal Year 2000. Secure support for the National Institutes of Health within the conference agreement on the Departments of Labor, Health and Human Services, and Education and Related Appropriations bill. Overall NIH funding as well as salary cap for investigators and extramural research facilities construction were priorities.

H.J. Res. 80 - Making continuing appropriations for Fiscal Year 2000 and other purposes. Tracked and monitored legislation.

H.J. Res. 82 - Making continuing appropriations for Fiscal Year 2000 and other purposes. Tracked and monitored legislation.

H.J. Res. 83 - Making continuing appropriations for Fiscal Year 2000 and other purposes. Tracked and monitored legislation.

H.J. Res. 84 - Making continuing appropriations for Fiscal Year 2000 and other purposes. Tracked and monitored legislation.

H.J. Res. 68 - Making continuing appropriations for Fiscal Year 2000 and other purposes. Tracked and monitored legislation.

H.J. Res. 71 - Making continuing appropriations for Fiscal Year 2000 and other purposes. Tracked and monitored legislation.

H.J. Res. 73 - Making continuing appropriations for Fiscal Year 2000 and other purposes. Tracked and monitored legislation.

H.J. Res. 75 - Making continuing appropriations for Fiscal Year 2000 and other purposes. Tracked and monitored legislation.

H.J. Res. 78 - Making continuing appropriations for Fiscal Year 2000 and other purposes. Tracked and monitored legislation.

S. Con. Res. 20, An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal years 2000 through 2009 -- tracked, monitored, reported consideration of legislation.

H.R. 1906, Appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies for the Fiscal Year 2000, Title VI: Secure support for funding for the Food and Drug Administration -- tracked, monitored, reported consideration of legislation.

S. 1233, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2000, Title VI: Secure support for funding for the Food and Drug Administration -- tracked, monitored, reported consideration of legislation.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

House
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Marguerite Donoghue Baxter		<input type="checkbox"/>
Ed Long		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____

Printed Name and Title Debra M. Hardy Havens, CEO

Registrant Name Capitol Associates, Inc. Client Name Glaxo Wellcome, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code CPT (one per page)

16. Specific lobbying issues

H.R. 209, An act to improve the ability of federal agencies to license federally owned inventions - tracked, monitored, reported consideration of legislation.

S. 804, An act to improve the ability of federal agencies to license federally owned inventions - tracked, monitored, reported consideration of legislation.

17. House(s) of Congress and Federal agencies contacted ☐ Check if None

House
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Marguerite Donoghue Baxter		<input type="checkbox"/>
Tricia Brooks		<input type="checkbox"/>
		<input type="checkbox"/>
		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above ☒ Check if None

Signature _____

Printed Name and Title Debra M. Hardy Havens, CEO

Form LD-2 (Rev. 06/98)

PAGE 3 of 4

Registrant Name Capitol Associates, Inc. Client Name Glaxo Wellcome, Inc.

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code MED (one per page)

16. Specific lobbying issues

H.R. 10, Financial Services Act of 1999, Title III, Subtitle D, The Confidentiality of Health and Medical Information -- tracked, monitored, reported consideration of legislation.

H.R. 1057, Medical Information Privacy and Security Act -- tracked, monitored, reported consideration of legislation.

H.R. 1941, Health Information Privacy Act -- tracked, monitored, reported consideration of legislation.

H.R. 2404, Personal Medical Information Protection Act of 1999 -- tracked, monitored, reported consideration of legislation.

H.R. 2455, Consumer Health and Research Technology Protection Act -- tracked, monitored, reported consideration of legislation.

H.R. 2470, Medical Information Protection and Research Enhancement Act of 1999 -- tracked, monitored, reported consideration of legislation.

S. 573, Medical Information Privacy and Security Act -- tracked, monitored, reported consideration of legislation.

S. 578, Health Care PIN Act -- tracked, monitored, reported consideration of legislation.

S. 881, Medical Information Protection Act of 1999 -- tracked, monitored, reported consideration of legislation.

H. Res. 89, A resolution to express the sense of the House of Representatives that the Federal investment in biomedical research should be increased by 2,000,000,000 in fiscal year 2000 -- tracked, monitored, reported consideration of legislation.

S. Res. 19, A resolution to express the sense of the Senate that the Federal investment in biomedical research should be increased by \$2,000,000,000 in fiscal year 2000 -- tracked, monitored, reported consideration of legislation.

Legislative initiatives relative to stem cell research.

Federal activities relative to expedited review.

17. House(s) of Congress and Federal agencies contacted

☐ Check if None

House
Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)	New
Marguerite Donoghue Baxter		<input type="checkbox"/>
Tricia Brooks		<input type="checkbox"/>

19. Interest of each foreign entity in the specific issues listed on line 16 above

☒ Check if None

Signature _____

Printed Name and Title Debra M. Hardy Havens, CEO

Form LD-2 (Rev. 06/98)

PAGE 4 of 4